Is Maternal Propranolol the Future of Fetal Surgery?

Placental chorioangiomas, which are benign vascular tumors of the placenta, present a significant therapeutic challenge in obstetrics. These vascular masses can lead to severe complications, specifically fetal high-output cardiac failure. Historically, clinicians relied on highly invasive fetal surgeries with high mortality rates. Consequently, maternal propranolol for chorioangioma offers a highly promising, non-invasive option. Indeed, this therapy may soon revolutionize prenatal care.

Understanding the Risks of Giant Placental Chorioangiomas

Giant chorioangiomas measure more than four centimeters in diameter and can cause maternal-fetal complications. Specifically, they act as large arteriovenous shunts that divert blood away from the fetus. This shunting forces the fetal heart to work much harder. As a result, the fetus often develops hyperdynamic circulation, cardiomegaly, and severe hydrops fetalis. In the past, medical teams managed these high-risk cases using invasive procedures. These techniques included fetoscopic laser photocoagulation and intratumoral embolization. However, these surgeries show limited success and carry high fetal mortality rates. Therefore, researchers sought a safer pharmacological solution to avoid these procedural risks.

Why Maternal Propranolol for Chorioangioma is a Game-Changer

Biologically, placental chorioangiomas share striking similarities with infantile hemangiomas. Oral propranolol is the standard therapy for infantile hemangiomas. Therefore, clinicians proposed a similar mechanism for placental tumors. Propranolol acts as a non-selective beta-blocker that causes vasoconstriction and downregulates angiogenic factors. Consequently, maternal oral administration of propranolol can selectively target the placental tumor. This treatment path protects overall placental function while avoiding invasive fetal interventions. Furthermore, maternal propranolol easily crosses the placental barrier, which ensures the drug reaches the tumor directly. This established safety profile makes propranolol a highly attractive, off-label alternative for symptomatic pregnancies.

Key Clinical Findings and Outcomes

A landmark case series from Leiden University Medical Center evaluated this innovative therapy. Specifically, the study followed four fetuses presenting with giant chorioangiomas and signs of severe heart failure. The mothers took oral propranolol to stabilize fetal hemodynamics. Incredibly, the fetal condition improved significantly in all cases after initiating treatment. The fetal cardiac function normalized rapidly, and the life-threatening hydrops fetalis resolved completely. Additionally, post-delivery histological examinations confirmed tumor regression and extensive thrombosis. Clearly, these results suggest that maternal beta-blocker therapy can reduce the need for high-risk fetal surgeries.

Frequently Asked Questions

Q1: Why is maternal propranolol considered for placental chorioangiomas?

Placental chorioangiomas share biological and structural characteristics with infantile hemangiomas. Therefore, propranolol can selectively target and shrink these placental tumors by causing vasoconstriction.

Q2: What are the main fetal complications associated with large chorioangiomas?

Large placental chorioangiomas often cause hyperdynamic fetal circulation, high-output cardiac failure, and severe non-immune hydrops fetalis. Consequently, these complications carry a very high risk of fetal demise if left untreated.

Q3: How does maternal propranolol therapy compare to traditional fetal surgery?

Traditional fetal surgery, such as laser coagulation or embolization, is highly invasive and carries significant risks of fetal mortality. In contrast, oral maternal propranolol is a non-invasive, pharmacological treatment that demonstrates excellent safety and efficacy profiles.

References

1. van der Meeren LE et al. Maternal propranolol as a safe alternative to invasive fetal surgery in chorioangioma management. Ultrasound Obstet Gynecol. 2026 Jul 06. doi: 10.1002/uog.70272. PMID: 42406825.
2. Padys P, Fouque L, Le Duff M, Poulain P. Propranolol during pregnancy for large chorioangioma. Med Hypotheses. 2015 Oct;85(4):513-4. doi: 10.1016/j.mehy.2015.06.032. PMID: 26160051.
3. Le Vance J, Gurney L, Hodgetts Morton V, Morris RK, Marton T. Non-trophoblastic tumours of the placenta: pathophysiology, diagnosis and management. Obstetrician & Gynaecologist. 2025;27(2):91-103. doi: 10.1111/tog.12970.